Paxlovid

Protection against severe outcomes soared to 80% when the drug was dispensed within five days of symptom onset, compared with 54% efficacy outside that time frame, investigators found. 

The antiviral drug Paxlovid should receive full FDA approval to treat COVID-19 in older adults at risk of severe outcomes, the advisers decided in a Thursday vote.

Researchers from the University of Colorado School of Medicine say the prescription drug Paxlovid remains a very effective treatment against the COVID-19 omicron variants.

The FDA on Wednesday made it easier for clinicians to prescribe these antiviral drugs in cases where transmission is evident and the patient is at high risk of severe illness.

The CDC reports that COVID patients treated with the antiviral Paxlovid have a 51% lower risk of hospitalization, while another study has tied acute-care stays to muscle loss and long COVID.

Drug overdoses in seniors climb between 2000 and 2020 … Predictive clinical tool determines 5, 9 and 13-year risk of dementia … Remdesivir and corticosteroids tied to better COVID acute-care outcomes...

Investigators plan to test whether the antiviral drug Paxlovid will relieve symptoms of the syndrome known as long COVID, also called post-acute sequelae of COVID-19.

Five medical societies have created a toolkit designed to help clinicians increase the effectiveness, accessibility and awareness of oral antiviral therapeutics and COVID-19 booster vaccines.

Patients who had rebound symptoms after taking Paxlovid showed a more robust immune response to SARS-CoV-2 than patients with no rebound, investigators reported.

Pfizer’s COVID pill Paxlovid has profound effect in seniors, NEJM study finds … SNFs can access free COVID testing for staff, residents through Dec. 31 … Researchers identify risk of COVID and its...